X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Sohonos (palovarotene) is a selective agonist of RARγ, a receptor expressed in chondrogenic cells and chondrocytes that acts as a transcriptional repressor, which is investigated for the treatment of fibrodysplasia ossificans progressiva.
Lead Product(s): Palovarotene
Therapeutic Area: Genetic Disease Product Name: Sohonos
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2023
Details:
Sohonos (palovarotene) is a selective agonist of RARγ, a receptor expressed in chondrogenic cells and chondrocytes that acts as a transcriptional repressor. Palovarotene is the first medicine to be submitted for regulatory approval for fibrodysplasia ossificans progressiva.
Lead Product(s): Palovarotene
Therapeutic Area: Genetic Disease Product Name: Sohonos
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2023
Details:
Sohonos (palovarotene) is a selective agonist of RARγ, a receptor expressed in chondrogenic cells and chondrocytes that acts as a transcriptional repressor. It decreases BMP signaling and subsequently inhibits the SMAD1/5/8 signaling pathway.
Lead Product(s): Palovarotene
Therapeutic Area: Genetic Disease Product Name: Sohonos
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Details:
Palovarotene is authorized for use in appropriate patients in Canada and United Arab Emirates where it is marketed as SohonosTM (palovarotene capsules).4 Investigational palovarotene is under review with a number of regulatory authorities.
Lead Product(s): Palovarotene
Therapeutic Area: Genetic Disease Product Name: Sohonos
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2022
Details:
Sohonos (palovarotene) is an oral investigational, selective retinoic-acid receptor gamma (RARγ) agonist being developed as a potential treatment for people living with the debilitating ultra-rare genetic disorder fibrodysplasia ossificans progressiva (FOP).
Lead Product(s): Palovarotene
Therapeutic Area: Genetic Disease Product Name: Sohonos
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022
Details:
Sohonos (palovarotene), an oral selective retinoic-acid receptor gamma (RARγ) agonist approved by Health Canada indicated to reduce the formation of heterotopic ossification in adults and children with fibrodysplasia ossificans progressiva.
Lead Product(s): Palovarotene
Therapeutic Area: Genetic Disease Product Name: Sohonos
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2022
Details:
Analysis of the primary endpoint data demonstrated a 62% reduction in mean annualised new HO volume in participants treated with palovarotene versus untreated participants from a natural-history study.
Lead Product(s): Palovarotene
Therapeutic Area: Genetic Disease Product Name: IPNG 60120
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2021
Details:
The presentation will highlight data from Ipsen’s MOVE trial, the first and only multicenter Phase III study in fibrodysplasia ossificans progressiva.
Lead Product(s): Palovarotene
Therapeutic Area: Genetic Disease Product Name: IPNG 60120
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
Details:
Post hoc analyses showed substantial reduction (62%) in mean annualized new heterotopic ossification volume in patients with FOP who were treated with oral investigational therapy palovarotene.
Lead Product(s): Palovarotene
Therapeutic Area: Genetic Disease Product Name: IPNG 60120
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
The data include a first-of-its kind study highlighting one-year data on the natural progression of FOP and the impact of heterotopic ossification (HO) on patients’ physical functioning over time.
Lead Product(s): Palovarotene
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2020
Details:
Ipsen to conduct further assessment of the complete data set and work with the regulatory authorities, based on encouraging therapeutic activity signals observed in preliminary post-hoc analyses.
Lead Product(s): Palovarotene
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
